Literature DB >> 12858123

Managing renal arterial disease and hypertension.

Stephen C Textor1.   

Abstract

Treating patients with renovascular disease is complex, particularly as imaging and medical techniques become more effective. Atherosclerotic renal artery disease is present in 7% of the general population above age 65 and in 20 to 45% of patients with coronary disease or aortoiliac disease. Most patients are treated medically, but when progressive hypertension, renal insufficiency, or circulatory congestion develops, revascularization should be considered. Endovascular procedures with arterial stents are now widely employed. These procedures sometimes offer major benefits in blood pressure control and stabilization of renal function. Stent procedures continue to entail hazards, including atheroemboli, arterial dissections, and thrombosis, in addition to restenosis rates of 14 to 20%. Small, randomized trials to date demonstrate no survival benefit to either endovascular or surgical revascularization as compared with medical management. Recognizing renal artery disease and directing revascularization procedures to those with the most benefit remains a premier challenge for the clinician.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12858123     DOI: 10.1097/00001573-200307000-00004

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  8 in total

1.  Genetic deficiency of Smad3 protects the kidneys from atrophy and interstitial fibrosis in 2K1C hypertension.

Authors:  Gina M Warner; Jingfei Cheng; Bruce E Knudsen; Catherine E Gray; Ansgar Deibel; Justin E Juskewitch; Lilach O Lerman; Stephen C Textor; Karl A Nath; Joseph P Grande
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-29

2.  Development of renal atrophy in murine 2 kidney 1 clip hypertension is strain independent.

Authors:  Sonu Kashyap; Rajendra Boyilla; Paula J Zaia; Roba Ghossan; Karl A Nath; Stephen C Textor; Lilach O Lerman; Joseph P Grande
Journal:  Res Vet Sci       Date:  2016-06-08       Impact factor: 2.534

3.  Temporal analysis of signaling pathways activated in a murine model of two-kidney, one-clip hypertension.

Authors:  Jingfei Cheng; Wei Zhou; Gina M Warner; Bruce E Knudsen; Vesna D Garovic; Catherine E Gray; Lilach O Lerman; Jeffrey L Platt; J Carlos Romero; Stephen C Textor; Karl A Nath; Joseph P Grande
Journal:  Am J Physiol Renal Physiol       Date:  2009-07-22

4.  Elastin haploinsufficiency induces alternative aging processes in the aorta.

Authors:  Mylène Pezet; Marie-Paule Jacob; Brigitte Escoubet; Dealba Gheduzzi; Emmanuelle Tillet; Pascale Perret; Philippe Huber; Daniela Quaglino; Roger Vranckx; Dean Y Li; Barry Starcher; Walter A Boyle; Robert P Mecham; Gilles Faury
Journal:  Rejuvenation Res       Date:  2008-02       Impact factor: 4.663

Review 5.  Management of renal artery stenosis: What does the experimental evidence tell us?

Authors:  Mohammed Al-Suraih; Joseph Peter Grande
Journal:  World J Cardiol       Date:  2014-08-26

6.  Angiotensin II augments renal vascular smooth muscle soluble GC expression via an AT1 receptor-forkhead box subclass O transcription factor signalling axis.

Authors:  Joseph C Galley; Scott A Hahn; Megan P Miller; Brittany G Durgin; Edwin K Jackson; Sean D Stocker; Adam C Straub
Journal:  Br J Pharmacol       Date:  2021-06-09       Impact factor: 9.473

7.  Redox signaling is an early event in the pathogenesis of renovascular hypertension.

Authors:  Stella P Hartono; Bruce E Knudsen; Adeel S Zubair; Karl A Nath; Stephen J Textor; Lilach O Lerman; Joseph P Grande
Journal:  Int J Mol Sci       Date:  2013-09-10       Impact factor: 5.923

Review 8.  Atherosclerotic renal artery stenosis and renovascular hypertension: clinical diagnosis and indications for revascularization.

Authors:  Edmund Kenneth Kerut; Stephen A Geraci; Chester Falterman; David Hunter; Curtis Hanawalt; Thomas D Giles
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-07       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.